---
schema_version: "secwatch.filing_event.v1"
accession: "0001326190-24-000006"
form_type: "8-K"
ticker: "ALT"
cik: "0001326190"
company_name: "Altimmune, Inc."
filed_at: "2024-03-27T23:59:59+00:00"
generated_at: "2026-06-04T07:01:01.090209+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Altimmune reports Q4 net loss $31.6M; positive pemvidutide body composition data; HepTcell discontinued

## Summary
- Net loss $31.6M ($0.54/share) for Q4 2023, including $12.4M impairment for discontinued HepTcell program.
- Cash $198.0M; body composition: 74.5% weight loss from fat, 25.5% from lean mass on pemvidutide.
- MOMENTUM: 15.6% mean weight loss at 48 weeks on 2.4 mg pemvidutide; >30% achieved ≥20% weight loss.
- IMPACT Phase 2b MASH trial enrollment ongoing; topline 24-week data expected Q1 2025.
- HepTcell development stopped; overall response in Phase 2 insufficient to warrant further advancement.

## SEC filing metadata
- accession: 0001326190-24-000006
- form_type: 8-K
- ticker: ALT
- cik: 0001326190
- company_name: Altimmune, Inc.
- filed_at: 2024-03-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326190/000132619024000006/0001326190-24-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326190/000132619024000006/alt-20240327x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326190-24-000006
- JSON: https://secwatch.observer/filing/0001326190-24-000006.json
- Plain text: https://secwatch.observer/filing/0001326190-24-000006.txt

## Key facts
- Earnings Releases
  Altimmune, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Result: reported results
  source text: Altimmune, Inc. (the “Company”) issued a press release announcing the Company’s financial results for its full year and fiscal quarter ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326190/000132619024000006/0001326190-24-000006-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.